Skip to main content
Fig. 9 | Molecular Neurodegeneration

Fig. 9

From: Prophylactic melatonin significantly reduces Alzheimer’s neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPPswe/PS1 mice

Fig. 9

Complex IV activity in striatal extracts from 13- and 16-month mice. There was a decline in complex IV activity in NonAD mice and an increase in complex IV activity in AD mice from 13 to 16 months irrespective of MEL receptor status. a At 13 months 2xAD/MTNR+ mice had higher complex IV activity than 2xAD/MTNR- mice (p = 0.03). MEL treatment of the 2xAD/MTNR+ mice decreased complex IV activity (*p = 0.03). b At 16 months NonAD/MTNR+ mice had higher complex IV activity than NonAD/MTNR- mice (*p = 0.005) and 2xAD/MTNR+ mice had higher complex IV activity than 2xAD/MTNR- mice (*p = 0.02). MEL treated 16 month mice had higher complex IV activity in both NonAD/MTNR+ (*p < 0.001) and NonAD/MTNR- (*p < 0.001) groups. MEL treatment prevented the increased complex IV activity in 2xAD/MTNR+ mice (*p < 0.001). MEL treatment of NonAD/ MTNR- mice did not restore complex IV activity to the level present in NonAD/ MTNR+ mice (*p < 0.05). Evaluated with 2-way ANOVA; error bars represent SEM

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326